139 related articles for article (PubMed ID: 6821325)
21. Enzyme replacement for lysosomal diseases.
Brady RO
Annu Rev Med; 2006; 57():283-96. PubMed ID: 16409150
[TBL] [Abstract][Full Text] [Related]
22. [Hereditary diseases caused by disorders in glycoconjugate metabolism].
Rozenfel'd EL
Vopr Med Khim; 1977; (1):3-12. PubMed ID: 404759
[No Abstract] [Full Text] [Related]
23. Letter: Intestinal biopsy in lysosomal storage disease.
Den Tandt WR; Vio PM; Eggermont E
Lancet; 1974 Nov; 2(7889):1149. PubMed ID: 4139453
[No Abstract] [Full Text] [Related]
24. [Enzyme replacement therapy for lysosomal storage disorders].
Valayannopoulos V; Brassier A; Chabli A; Caillaud C; Lemoine M; Odent T; Arnoux JB; de Lonlay P
Arch Pediatr; 2011 Oct; 18(10):1119-23. PubMed ID: 21873040
[TBL] [Abstract][Full Text] [Related]
25. Plasma methylumbelliferyl-tetra-N-acetyl-beta-d-chitotetraoside hydrolase as a parameter during treatment of gaucher patients.
Den Tandt WR; Van Hoof F
Biochem Mol Med; 1996 Feb; 57(1):71-2. PubMed ID: 8812729
[No Abstract] [Full Text] [Related]
26. [Type II glycogenosis. Example of congenital lysosomal disease].
de Barsy T
Acta Neurol (Napoli); 1973; 28(4):369-75. PubMed ID: 4202099
[No Abstract] [Full Text] [Related]
27. Metabolic disorders and corneal changes.
François J
Dev Ophthalmol; 1981; 4():1-69. PubMed ID: 6795067
[No Abstract] [Full Text] [Related]
28. The effect of enzyme therapy in a patient with Gaucher disease type III.
Bosman DK; Hollak CE; Aerts JM; Bakker HD
J Inherit Metab Dis; 1996; 19(5):703-4. PubMed ID: 8892032
[No Abstract] [Full Text] [Related]
29. Enzymatic and biochemical diagnosis of inborn lysosomal diseases with neurological symptoms.
Hultberg B; Ockerman PA; Sjöblad S
Eur Neurol; 1972; 7(1):101-18. PubMed ID: 4259742
[No Abstract] [Full Text] [Related]
30. Changes in serum chitotriosidase activity with cessation of replacement enzyme (cerebrosidase) administration in Gaucher disease.
Czartoryska B; Tylki-Szymańska A; Lugowska A
Clin Biochem; 2000 Mar; 33(2):147-9. PubMed ID: 10751594
[No Abstract] [Full Text] [Related]
31. Evolving features in type 3 Gaucher disease on long-term enzyme replacement therapy.
Elstein D; Abrahamov A; Altarescu G; Zimran A
Blood Cells Mol Dis; 2013 Feb; 50(2):140. PubMed ID: 23085428
[No Abstract] [Full Text] [Related]
32. [Characteristics of biochemical disorders in hereditary enzymopathies in humans and animals].
Rozenfel'd EL
Vopr Med Khim; 1982; 28(3):2-7. PubMed ID: 6125053
[No Abstract] [Full Text] [Related]
33. Reduction in imiglucerase dosage causes immediate rise of chitotriosidase activity in patients with Gaucher disease.
Chien YH; Lee NC; Tsai FJ; Chao MC; Hwu WL
Mol Genet Metab; 2010 Sep; 101(1):90-1. PubMed ID: 20580583
[No Abstract] [Full Text] [Related]
34. [Inborn errors of metabolism in muscle cells].
Sengers RC; Stadhouders AM; Trijbels JM; Bookelman H
Ned Tijdschr Geneeskd; 1977 Mar; 121(12):493-9. PubMed ID: 321979
[No Abstract] [Full Text] [Related]
35. Persistent bone disease in adult type 1 Gaucher disease despite increasing doses of enzyme replacement therapy.
de Fost M; van Noesel CJ; Aerts JM; Maas M; Pöll RG; Hollak CE
Haematologica; 2008 Jul; 93(7):1119-20. PubMed ID: 18519519
[No Abstract] [Full Text] [Related]
36. Diagnosis and prenatal diagnosis of lysosomal storage diseases.
Shi HP; Guo YF; Zhang WM; Yuan LF; Luo HY; Sun NH; Zhao SM; Zhu MG
Chin Med J (Engl); 1988 Jun; 101(6):383-7. PubMed ID: 3146466
[No Abstract] [Full Text] [Related]
37. [Lysosomal storage diseases: clinical variety and genetic heterogeneity (author's transl)].
Gitzelmann R; Wiesmann UN; Spycher MA
Verh Dtsch Ges Pathol; 1976; ():101-5. PubMed ID: 828812
[No Abstract] [Full Text] [Related]
38. The role of lysosomes in the pathogeny of storage diseases.
Hers HG
Arch Belg Dermatol Syphiligr; 1972; 28(1):51-7. PubMed ID: 4266285
[No Abstract] [Full Text] [Related]
39. Pharmacologic chaperoning as a strategy to treat Gaucher disease.
Yu Z; Sawkar AR; Kelly JW
FEBS J; 2007 Oct; 274(19):4944-50. PubMed ID: 17894779
[TBL] [Abstract][Full Text] [Related]
40. [Gaucher disease type 1--therapeutic results of enzyme substitution].
Steensberg J; Nielsen KG; Brandt NJ
Ugeskr Laeger; 1998 Jun; 160(26):3929-30. PubMed ID: 9656836
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
